Study of How Safe and Effective Tarlatamab is in Brain Cancers
Status:
RECRUITING
Trial end date:
2028-03-03
Target enrollment:
Participant gender:
Summary
This is a phase 2 study to assess how useful study drug tarlatamab is for the treatment of patients with recurrent/refractory oligodendroglioma or astrocytoma with a mutation in the IDH gene.